Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Clinical trial NCT02570542 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02570542
Sponsor: Memorial Sloan Kettering Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma (DLBCL)Relapsed Diffuse Large B-cell Lymphoma (DLBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Start date: 2015-10-01
Primary completion: 2026-10-01
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.